What To Expect From Barclays PLC And Standard Chartered PLC Results

Will results from Barclays PLC (LON: BARC) and Standard Chartered PLC (LON: STAN) please shareholders?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The first week in March brings us the final two sets of full-year results from the FTSE 100‘s big bankers, with Barclays (LSE: BARC)(NYSE: BCS.US) set to report on 3 March and Standard Chartered (LSE: STAN)(NASDAQOTH: SCBFF.US) a day later.

Both have had very different rides since the banking crisis unfolded, and both have very different forecasts.

Back to strong growth

For Barclays, the City is predicting three years of double-digit growth starting with 2014’s figures, with the dividend climbing back up to yields not see since before the crash — the expected 2014 yield is down at a modest 2.5%, but forecasts see that ramping up to 3.6% in 2015 and 4.6% in 2016 on a share price of 262p.

Adjusted pre-tax profit for the nine months to September was up 5% to £4,939m, with asset values up and operating expenses falling — big redundancies over the previous 12 months made a significant difference to the latter. Liquidity ratios were up, with a CET1 of 10.2%, and Barclays went on to satisfy the Bank of England stress tests in December.

We’ve had 3p per share in dividends so far this year, and all in all, the current forecasts are likely to be pretty close to the mark. With a P/E ratio of under 13 based on expectations for 2014, dropping to under 9 for 2016 forecasts, I still rate Barclays a Buy.

Troubled management

Things are different at Standard Chartered, whose focus on Asia helped protect it from the bulk of the Western banking woes. But the bank has been suffering problems of its own, with its South Korean division performing badly, and that’s helped the shares to a 28% loss over 12 months.

We’ve had a chorus of complaints about board-level management, and Standard Chartered bowed to the inevitable on Thursday. Beleaguered chief executive Peter Sands is to be replaced by Bill Winters, with chairman Sir John Peace and Asia CEO Jaspal Bindra, along with 3 non-executives, making their exits too.

Forecasts suggest a 5% EPS fall for 2014, and only a very modest recovery in 2015. But dividend yields are expected to remain above 5%. With first-half pre-tax profit falling 20%, the interim dividend was held flat and cover still seems reasonable, and the bank’s liquidity ratios look more than adequate — a cut in the final payment would come as a shock now.

New strategy?

However the actual figures turn out, eyes will surely be peeled for a change in strategic direction now that there’s new top management on board. And that’s already pleased the market, with Standard Chartered shares up 3% to 954p since the shakeup announcement.

Standard Chartered’s P/E valuation is significantly lower than Barclays’, falling from a current 8.9 to only 7.7 on 2016 forecasts. If you trust the new bosses to at least do no worse, it would be worth an investment.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Alan Oscroft has no position in any shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Stacks of coins
Investing Articles

1 penny stock mistake to avoid in 2025

Ben McPoland explores a rookie error common to penny stock investing, and also highlights a 19p small-cap that looks like…

Read more »

Warren Buffett at a Berkshire Hathaway AGM
Investing Articles

What can Warren Buffett teach an investor with £1,000?

Although Warren Buffett’s a billionaire, his investing lessons can be applied to far more modest portfolios. Our writer explains some…

Read more »

Light bulb with growing tree.
Investing Articles

Down 43%, could the ITM share price start rising again in 2025?

After news of the latest sales deal being inked, our writer revisits the ITM share price and considers if the…

Read more »

Runner standing at the starting point with 2025 year for starting in new year 2025 to achieve business planing and success concept.
Investing Articles

Is 2024’s biggest FTSE faller now the best share to buy for 2025?

Harvey Jones thought this FTSE 100 growth stock was the best share to buy for 2024, but was wrong. Yet…

Read more »

New year resolutions 2025 on desk. 2025 resolutions list with notebook, coffee cup on table.
Investing Articles

Legal & General has huge passive income potential with a forecast yield of almost 10% in 2025!

Harvey Jones got a fabulous rate of passive income from this top FTSE 100 dividend stock in 2024, and believes…

Read more »

Investing Articles

This stock market dip is my chance to buy cheap FTSE shares for 2025!

Harvey Jones was looking forward to a Santa Rally in December, but it looks like we're not going to get…

Read more »

Investing Articles

Analysts are saying the AstraZeneca share price looks cheap despite China turmoil

The AstraZeneca share price could be considerably undervalued according to analysts. Dr James Fox takes a closer look at the…

Read more »

Pink 3D image of the numbers '2025' growing in size
Investing Articles

1 FTSE 100 stock I expect to outperform in 2025

Can the integration of its big acquisition from 2022 finally lead Rentokil Initial to outperform the FTSE 100 next year?…

Read more »